Natera Reports Signatera Helped Predict Lymphoma Outcomes And Treatment Response
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in
Natera's cancer blood test called Signatera showed it can help doctors predict how well lymphoma patients will do and how they'll respond to treatment. This kind of scientific proof that a medical tool actually works is important for a company's reputation and future sales.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.